Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00660010 · ClinicalTrials.gov registry record · Phase 3
Study of Lupron Depot In The Treatment of Central Precocious Puberty
A Phase 3 study of Puberty, Precocious, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 9
- Study locations
NCT00660010 is a Phase 3 study of Puberty, Precocious that has completed, run by Abbott. The registered enrollment target is 55 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT00660010, a Phase 3 study of Puberty, Precocious, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.
Conditions Studied
Interventions
- DRUG Lupron (leuprolide acetate)
Study Locations (9)
California
- Site Reference ID/Investigator# 46671 - San Francisco
- Site Reference ID/Investigator# 14921 - Stanford
Arizona
- Site Reference ID/Investigator# 46673 - Phoenix
Colorado
- Site Reference ID/Investigator# 14343 - Aurora
Florida
- Site Reference ID/Investigator# 14341 - St. Petersburg
Indiana
- Site Reference ID/Investigator# 14342 - Indianapolis
Maryland
- Site Reference ID/Investigator# 46672 - Baltimore
Massachusetts
- Site Reference ID/Investigator# 46668 - Springfield
Pennsylvania
- Site Reference ID/Investigator# 14344 - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 1991-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00660010
The ClinicalTrials.gov registry entry for NCT00660010 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Puberty, Precocious appearing as the primary indexed condition, and to 1 intervention - of which Lupron (leuprolide acetate) is the first listed.
NCT00660010 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00660010 about?
NCT00660010 is a clinical study titled "Study of Lupron Depot In The Treatment of Central Precocious Puberty". The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.
What is the current status of trial NCT00660010?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 1991-01. Estimated completion is 2009-04.
What conditions does trial NCT00660010 study?
This clinical trial studies the following conditions: Puberty, Precocious.
What interventions are being tested in trial NCT00660010?
The interventions under investigation include: Lupron (leuprolide acetate) (DRUG).
Who is sponsoring clinical trial NCT00660010?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00660010 being conducted?
This trial has 9 study locations across Arizona, California, Colorado, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Puberty, Precocious
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.